1477 — Ocumension Therapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$4.43bn
- HK$3.64bn
- CNY417.31m
- 21
- 17
- 43
- 13
Annual income statement for Ocumension Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.1 | 56.1 | 159 | 246 | 417 |
| Cost of Revenue | |||||
| Gross Profit | 11.4 | 36.9 | 103 | 144 | 225 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,278 | 302 | 559 | 625 | 682 |
| Operating Profit | -2,265 | -246 | -400 | -378 | -265 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2,265 | -260 | -402 | -379 | -267 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,265 | -260 | -403 | -380 | -268 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,265 | -260 | -403 | -380 | -268 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,265 | -260 | -403 | -380 | -268 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.35 | -0.594 | -0.633 | -0.588 | -0.389 |